Background and Purpose-Low estimated glomerular filtration rate (eGFR) is known to be associated with clinical adverse outcomes. However, whether diabetes mellitus influences the association between eGFR and prognosis of stroke is still not elucidated. Methods-Prospective cohort of 17 280 (nondiabetic 12 498 and diabetic 4782) Chinese patients with acute stroke from the China National Stroke Registry and from abnormal glucose regulation in patients with acute stroke across China (ACROSS) between 2007 and 2009 were followed-up for 1 year for all-cause mortality, stroke recurrence, and stroke disability related to baseline eGFR in the presence and absence of diabetes mellitus. Results-Among nondiabetic patients, as compared with eGFR of 90 to 119 mL/min per 1.73 m 2 , the adjusted odds ratio of lower eGFR of < 45 mL/min per 1.73 m 2 was 2.79 (95% confidence interval, 2.09-3.73) for all-cause mortality, 2.28 (1.74-2.98) for stroke recurrence, and 1.53 (1.16-2.01) for stroke disability; higher eGFR of ≥120 mL/min per 1.73 m 2 was just significantly associated with higher risk of all-cause mortality (odds ratio, 1.38; 95% confidence interval, 1.02-1.86) but not with other outcomes. In diabetic patients, the adjusted odds ratios of all-cause mortality, stroke recurrence, and stroke disability in lower eGFR were 2.16 (1.51-3.08), 1.43 (1.02-2.00), and 1.38 (0.98-1.95), respectively; higher eGFR was significantly associated with higher risks of all stroke outcomes. 
S troke has become the leading cause of death and adult disability in China. 1 Identifying and controlling strokerelated risk factors would be extremely important in secondary prevention of stroke. 2 Kidney dysfunction, characterized by low estimated glomerular filtration rate (eGFR), is not only associated with all-cause and cardiovascular mortality in general population but also linked with long-term clinical outcomes in patients with stroke. [3] [4] [5] However, whether the link between reduced eGFR and outcomes after acute stroke could be modified by the presence or absence of some particular diseases is still uncertain.
The prevalence of diabetes mellitus in China has been increasing significantly in the past 2 decades and is now reaching epidemic proportions. 6, 7 Because diabetes mellitus has been regarded as a potent risk factor for both stroke and kidney dysfunction, 8, 9 we hereby hypothesized that the association of kidney dysfunction and adverse outcomes after acute stroke could be modified by the existence of diabetes mellitus. We tested this hypothesis by assessing the pattern and magnitude of associations of eGFR with outcomes after acute stroke in diabetic versus nondiabetic patients with stroke recruited from the China National Stroke Registry.
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Methods

Study Participants
The study population was from the China National Stroke Registry (CNSR) between 2007 and 2008 and from abnormal glucose regulation in patients with acute stroke across China (ACROSS) between 2008 and 2009. ACROSS was a derivative study of CNSR, which meant that ACROSS framework was based on the pre-existing CNSR study. Briefly, CNSR is a national hospital-based, prospective cohort study designed to evaluate the quality of care for hospitalized patients with stroke and measure the clinical and functional outcomes at 12 months after disease onset. The rationale and design of CNSR have been described previously. 10 ACROSS is a prospective study aimed at investigating the prevalence and distribution of abnormal glucose regulation and assessing the impact of abnormal glucose regulation on the 1-year outcome among hospitalized patients with ischemic or hemorrhagic stroke. 11 The reason for combination of these studies was that the same basic characteristic variables were collected and that the same outcome measures were assessed in the 2 cohorts. Of 25 666 patients from CNSR (22 216 ) and ACROSS (3450), 2508 (9.8%) patients were excluded because of undetermined diagnoses, incomplete information at baseline, hospitals transfers, and missing information of diabetes mellitus, leaving 23 158 patients with stroke for study sample ( Figure I in the online-only Data Supplement). Of 23 158 patients with or without diabetes mellitus, 5878 were excluded because of lack of serum creatinine on admission, missing 1-year follow-up information, and baseline age or sex (Table 1; Figure I in the online-only Data Supplement). Written informed consent was signed by patients or their legally authorized representatives. The study was approved by the central institutional review board at Beijing Tiantan Hospital.
Data Collection
Trained research coordinators of CNSR and ACROSS at each institute collected baseline information, including patient demographics, vascular risk factors, stroke severity (National Institutes of Health Stroke Scale [NIHSS]), medication use, imaging studies, diagnosis, and complications. Vascular risk factors included history of stroke, hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, coronary heart disease, current or previous smoking, and moderate or heavy alcohol consumption (≥2 standardized alcohol drinks per day). Diabetes mellitus was defined as fasting glucose level ≥7.0 mmol/L (126 mg/dL), the nonfasting glucose concentration ≥11.1 mmol/L (200 mg/dL) with classic symptoms of hyperglycemia or hyperglycemic crisis, any use of glucose-lowering drugs, or any self-reported history of diabetes mellitus. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, any use of antihypertensive drug, or self-reported history of hypertension. Dyslipidemia was defined as serum triglyceride ≥150 mg/ dL, low-density lipoprotein cholesterol ≥130 mg/dL, high-density lipoprotein cholesterol ≤40 mg/dL, any use of lipid-lowering drugs, or any self-reported history of dyslipidemia. Atrial fibrillation was defined as history of atrial fibrillation confirmed by ≥1 ECG or presence of the arrhythmia during hospitalization. Height and weight were measured with participants wearing a scrub suit and no shoes, and then body mass index was calculated by dividing weight in kilograms by the square of height in meters.
Kidney Function Measurement
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation with adjusted coefficient of 1.1 for the Asian population. 12, 13 Serum creatinine level was measured on admission using the Jaffe method and was reduced by 5% for the Chronic Kidney Disease Epidemiology Collaboration equation.
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Outcome Assessment
Follow-up was done by telephone interview. Data collection was performed by trained research personnel who were blinded to patients' baseline clinical status. They completed training modules on NIHSS and modified Rankin Scale and were certified. Patients were asked the standardized follow-up questions at 12 months after stroke onset. Outcome data collected included all-cause mortality, stroke recurrence, and stroke disability. Death was confirmed either by the death certificates from local citizen registries or from the treating hospitals. If such records were unavailable, death was confirmed if death was reported on 2 consecutive follow-up contacts with ≥2 different proxies. Recurrent stroke included ischemic stroke, intracranial hemorrhage, and subarachnoid hemorrhage. Recurrent stroke end points comprised fatal stroke and nonfatal stroke. We also evaluated the composite of death or recurrent stroke in the prognostic analysis. Stroke disability was defined as modified Rankin Scale of 2 to 6.
Statistical Analysis
eGFR values were categorized into 5 categories: <45, 45 to 59, 60 to 89, 90 to 119, and ≥120 mL/min per 1.73 m 2 according to the new classification for chronic kidney disease assessment and management; patients with eGFR of <45 mL/min per 1.73 m 2 were pooled together because of having relatively poor outcomes and patients with high eGFR of 120 mL/min per 1.73 m 2 were separated from patients with eGFR of ≥90 mL/min per 1.73 m 2 because of muscle loss related to malnutrition or kidney hyperfiltration in diabetics. 15 eGFR of 90 to 119 mL/min per 1.73 m 2 was served as the reference group in analysis. We compared baseline and clinical characteristics of patients according to eGFR levels in both diabetes mellitus and no diabetes mellitus groups. Continuous variables are expressed as mean with SD or medians with interquartile ranges, as appropriate. Categorical data are presented as proportions. Medians were imputed for missing continuous variables (body mass index and NIHSS) and modes were used to replace categorical variables (smoking status). Distributions of eGFR in patients with or without diabetes mellitus were estimated using kernel method with the Sheather-Jones plug-in approach for selecting the bandwidth (bandwidth multiplier=1).
We evaluated the association between eGFR and clinical outcomes among all patients stratified by diabetes mellitus using a logistic regression model with study sites as random effects adjusting for covariates of age, sex, history of stroke, hypertension, dyslipidemia, atrial fibrillation, coronary heart disease, smoking, alcohol, body mass index at admission, baseline NIHSS, pneumonia, and urethral infection. To examine effect modification by diabetes mellitus, we Finally, we further evaluated the pattern and magnitude of associations between eGFR and risks of adverse stroke outcomes using a logistic regression model with restricted cubic splines for eGFR among diabetic or nondiabetic patients adjusting for covariates. eGFR of 90 mL/min per 1.73 m 2 in patients with or without diabetes mellitus was treated as the individual reference and the 6 knots for spline were placed at 30, 45, 60, 90, 120, and 150 mL/min per 1.73 m 2 . All analyses were conducted with SAS Version 9.2 software (SAS Institute). Two-tailed P values <0.05 were considered to be statistically significant.
Results
Study Participants and Characteristics
A total of 17 280 (nondiabetic 12 498 and diabetic 4782) patients were included in the final analysis. Overall, regardless of diabetes mellitus status at baseline, participants with lower eGFR were more likely to be women, nonsmoker, nondrinker, and to have lower body mass index at baseline, higher NIHSS on admission, higher prevalence of hypertension, atrial fibrillation, coronary heart disease, history of stroke, and infection, whereas participants with higher eGFR had reverse characteristics of those with lower eGFR, when compared with normal range of eGFR 90 to 119 mL/min per 1.73 m 2 ( Table 2 ). The distribution of eGFR values based on the Kernel density estimation in both diabetic and nondiabetic participants is observed in Figure 1 . Table 3 shows the 1-year incidence of stroke outcomes including all-cause death, stroke recurrence, composite of death or stroke recurrence, and stroke disability, across eGFR categories. Risks of all end points increase with reduced eGFR and, moreover, these rates in diabetic or nondiabetic patients are similar within groups of eGFR <60 mL/min per 1.73 m 2 . However, nondiabetic participants with higher eGFR tend to have slightly lower proportions of end points, whereas diabetic patients with higher eGFR have relatively higher incidence, as compared with those with normal range of eGFR. Incidences in participants stratified by different subtypes of stroke are reported in Table I in the online-only Data Supplement.
Association of eGFR With Outcomes
Odds ratios (ORs) of stroke outcomes based on categories of eGFR and stratified by diabetes mellitus status are reported in Table 4 . Among nondiabetic patients, as compared with eGFR of 90 to 119 mL/min per 1.73 m 2 , the adjusted ORs of eGFR of <45 mL/min per 1.73 m 2 were 2.79 (95% confidence interval, 2.09-3.73) for all-cause mortality, 2.28 (1.74-2.98) 41-2.53 ), respectively. We also identified significantly statistical interactions between diabetes mellitus and categories of eGFR for all stroke end points (P=0.03, 0.01, 0.001, and 0.03 for death, recurrence, composite end point, and stroke disability, respectively). ORs for stroke outcomes in patients stratified by different subtypes of stroke are presented in Table II (ischemic stroke) and Table  III (hemorrhagic stroke) in the online-only Data Supplement. Other predictors for each of 4 stroke outcomes among entire population were also reported with OR in Table IV in the online-only Data Supplement.
Finally, we used the logistic regression model with restricted cubic spline to evaluate the pattern and magnitude of association between eGFR and stroke outcomes adjusted for covariates. We found a reverse J-shaped association between eGFR and all-cause death in nondiabetic and diabetic patients, but the risk gradient in increased level of eGFR is steeper in patients with diabetes mellitus than those without diabetes mellitus (Figure 2A and 2B). J shape was not observed for association between eGFR and stroke recurrence in nondiabetics, and yet still remained in diabetics ( Figure 2C and 2D) . With regard to combined end point or stroke disability, the results are similar to those of all-cause death or stroke recurrence ( Figure II in the online-only Data Supplement).
Discussion
In this national cohort of patients with acute stroke, decreased eGFR was associated with all-cause mortality, stroke recurrence, and stroke disability in both diabetic and nondiabetic patients, whereas increased eGFR was associated with all adverse stroke outcomes in diabetic patients and only linked to all-cause mortality in nondiabetic patients; the magnitudes of association of stroke outcomes with high eGFR level were more pronounced in diabetic group than that in nondiabetic group. Taken together, these findings highlight the importance of reduced eGFR as a predictor of stroke outcomes in the presence or absence of diabetes mellitus. Besides, increased eGFR might have a potential role in predicting stroke outcomes. To our knowledge, this is the first study in the national level to compare the influence of kidney dysfunction on outcomes after acute stroke in diabetic versus nondiabetic patients from China.
A growing body of evidence suggests that eGFR is an important predictor of all-cause and cardiovascular mortality, kidney failure, and stroke in the general population. [16] [17] [18] The pattern of the link between eGFR and all-cause mortality was described as J-shaped in the Cardiovascular Health Study. 19 In contrast, Mostofsky 20 reported U-shaped relationship between eGFR and all-cause mortality in 1175 patients with acute ischemic stroke, they thought that both decreased and increased eGFR were associated with a higher risk of mortality compared with the normal range of eGFR. As the results of previous studies were inconsistent, we further explored the pattern and magnitude of this association. Our study demonstrated that the patterns of these associations between decreased eGFR and all outcomes are much the same in the presence or absence of diabetes mellitus, despite those curves had different characteristics between nondiabetics and diabetics in higher level of eGFR (Table 4 ; Figure 2 ). Our study not only confirms the results of previous meta-analysis that patients with or without diabetes mellitus have similar risks of mortality linked with decreased eGFR 21 but also extends the association of reduced eGFR with other clinical end points like stroke recurrence or stroke disability. Thus, our results suggest that decreased eGFR would be able to be applied into clinical risk stratification for the prognosis of patients with acute stroke. 
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Our study also showed that increased eGFR was linked with higher risk of all-cause mortality regardless of diabetes mellitus status, yet the risk gradient is steeper in patients with diabetes mellitus than those without diabetes mellitus (Table 4 ; Figure 2 ). In addition, it is only in diabetic patients that association between increased eGFR and other 2 end points including stroke recurrence and stroke disability was found to be statistical significant, but not in nondiabetics. The relationship between increased eGFR and all-cause mortality in our study was in line with that of a recent cohort in general populations. 22 Although we have seen the association between increased eGFR and stroke outcomes, these results should be interpreted cautiously with the reason that increased eGFR may not always correspond to real high level of eGFR in some situations, such as lower muscle mass, inflammation, differences in body composition, or undiagnosed malignancy accounting for the excess mortality. 23, 24 It is likewise worth mentioning that, except for those confounding factors, kidney hyperperfusion is an important pathophysiological feature in diabetic patient, which is usually manifested as higher levels of eGFR. 25 This might be one of the important reasons of the association of increased eGFR and stroke outcomes existing in diabetic patients. However, we cannot exclude the possible influence by residual confounders that we mentioned above. Therefore, future work should try to validate our analyses in representative samples with less confounding factors and even include applying new biomarkers of kidney function like cystatin C in future study.
Strengths of our study include a large sample size of patients with stroke from China. It also contains outcomes of interest such as stroke recurrence and stroke disability in our study to reflect the prognosis of stroke. In addition, we used a new eGFR calculating equation to improve risk prediction.
14 Nonetheless, some limitations should be noticed while interpreting our results. First, albuminuria has proved to be an important independent risk factor for the adverse clinical outcomes in many diseases and was not included in our study, thus we were unable to evaluate eGFR and albuminuria simultaneously along with other factors in our patients. Second, as our cohort only comprised Chinese adult patients with stroke, these results may not be generalizable to other races and ethnicities. Third, patients with missing baseline serum creatinine or lost follow-up within 1 year were not included in the study, so a selection bias might exist, such as discrepancy in previous stroke and infection.
In conclusion, decreased eGFR is a strong predictor of allcause mortality, stroke recurrence, and stroke disability in diabetic and nondiabetic patients with acute stroke. Although increased eGFR is associated with all of stroke outcomes in diabetic patients and linked to all-cause mortality in nondiabetic patients, the results should be explained carefully because of the confounding like lower muscle mass and inflammation. Our study suggests that kidney dysfunction should be paid more attention in secondary prevention of stroke, especially in patients with diabetes mellitus. Table I . One-year incidence of clinical outcomes in diabetic and non-diabetic patients according to eGFR categories Table II . Odds ratios for the association between eGFR levels and clinical outcomes in diabetic and non-diabetic patients with Ischemic stroke Table III . Odds ratios for the association between eGFR levels and clinical outcomes in diabetic and non-diabetic patients with ICH or SAH Table IV . Independent predictors for 1-year all-cause mortality, stroke recurrence, combined endpoint and stroke disability among the entire population 
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